论文部分内容阅读
目的分析低剂量顺铂联合吉西他滨(GP方案)对老年非小细胞肺癌的治疗效果及安全性。方法 70例老年非小细胞肺癌患者,随机分为对照组(35例)与观察组(35例),分别采用常规剂量GP方案与低剂量GP方案,对比两组间治疗效果及毒副反应。结果两组患者间治疗总有效率、中位生存期及生存率比较,差异均无统计学意义(P>0.05);观察组的白细胞减少、恶心呕吐发生率均显著低于对照组,差异有统计学意义(P<0.05),两组间血小板减少、贫血发生率比较差异无统计学意义(P>0.05)。结论低剂量顺铂联合吉西他滨与常规剂量顺铂联合吉西他滨治疗老年非小细胞肺癌的临床疗效相近,但白细胞减少、恶心呕吐等毒副反应发生率均较少,患者耐受性好,可在临床借鉴应用。
Objective To analyze the efficacy and safety of low-dose cisplatin combined with gemcitabine (GP regimen) in the treatment of elderly non-small cell lung cancer. Methods Seventy patients with NSCLC were randomly divided into control group (35 cases) and observation group (35 cases). The routine and low dose GP regimens were used to compare the curative effect and adverse reactions between the two groups. Results There was no significant difference in the total effective rate, median survival time and survival rate between the two groups (P> 0.05). The incidences of leukopenia and nausea and vomiting in the observation group were significantly lower than those in the control group Statistical significance (P <0.05), thrombocytopenia between the two groups, the incidence of anemia was no significant difference (P> 0.05). Conclusions The clinical efficacy of low-dose cisplatin plus gemcitabine combined with gemcitabine in combination with gemcitabine is similar to that of gemcitabine in the treatment of elderly patients with non-small cell lung cancer. However, the incidence of toxic and side effects such as leukopenia and nausea and vomiting are low, and patients are well tolerated. Draw on the application.